Back to Program
MONTH 6

Acute Severe IBD & Inpatient Management

11.5h 8 CME 5 Sessions

Module Overview

Emergency management of acute severe ulcerative colitis (ASUC), complicated Crohn's disease, and the critical decision points between rescue therapy and surgery.

Benchmark Source: ECCO ASUC Guidelines + Mount Sinai Inpatient IBD Rotation

Learning Objectives

Apply the Oxford/Travis criteria for ASUC and initiate IV corticosteroids

Use day-3 response predictors (Travis criteria, CRP, stool frequency) for rescue therapy decisions

Manage toxic megacolon, perforation, and massive hemorrhage

Coordinate surgical timing with colorectal surgery team

Teaching Sessions

3h
Lecture

Acute Severe Ulcerative Colitis (ASUC): Day 1 to Day 7

A 3-hour comprehensive masterclass on the day-by-day inpatient management of acute severe UC: Truelove-Witts criteria, infection workup, IV steroids, day-3 response criteria, infliximab vs cyclosporine rescue, surgical timing, and Saudi-specific care pathways.

1Diagnosis and admission criteria: Truelove-Witts (30 min)

Truelove and Witts criteria define ASUC: ≥6 bloody stools/day PLUS ≥1 of: fever >37.8°C, tachycardia >90, anemia (Hgb <10.5), or ESR >30 or CRP >30. All ASUC patients require admission to a tertiary IBD center with surgical capability. Initial assessment: vital signs, abdominal examination (rule out toxic megacolon — abdominal distension, tympany, fever, tachycardia, leukocytosis), CBC, CMP, CRP, albumin, magnesium, phosphate, ESR, blood culture if febrile. Stool: C. difficile toxin PCR, multiplex enteric pathogen panel, ova and parasites. Imaging: AXR for colonic dilation (>5.5 cm = toxic megacolon, >9 cm small bowel dilation), avoid CT unless complication suspected. Flexible sigmoidoscopy WITHOUT bowel prep within 24-48h to confirm Mayo 3 endoscopic disease and exclude CMV.

Clinical Pearl

Sigmoidoscopy without bowel prep within 48h is essential — bowel prep can trigger perforation in severely inflamed colon. Use an unprepped exam to confirm Mayo 3 and biopsy for CMV.

Key Points
  • Truelove-Witts: ≥6 bloody stools/day + 1 systemic feature
  • Admit to tertiary center with colorectal surgery on call
  • Stool C. difficile toxin and pathogen panel mandatory
  • AXR daily; toxic megacolon >5.5 cm colonic dilation
  • Sigmoidoscopy without prep within 48h to biopsy for CMV

2Day 1-2 management: IV steroids, supportive care, VTE prophylaxis (30 min)

IV methylprednisolone 60 mg/day or hydrocortisone 100 mg q6h is first-line. Higher doses do NOT improve response. Supportive care: NPO if severe symptoms or planning surgery, IV fluids with K+ replacement, transfuse if Hgb <7-8 (or <9 in CV disease), correct hypoalbuminemia and hypomagnesemia, nutritional assessment within 48h. VTE prophylaxis MANDATORY: LMWH (enoxaparin 40 mg SC daily, or 30 mg if CrCl <30) — IBD patients have 3× VTE risk; rectal bleeding is NOT a contraindication. Avoid antimotility drugs (loperamide, opioids, NSAIDs) — risk of toxic megacolon. Antibiotics ONLY if culture positive, suspected perforation, or toxic megacolon. Discontinue 5-ASA (no role acutely).

Clinical Pearl

VTE prophylaxis with LMWH is MANDATORY in ASUC — IBD inflammation creates a hypercoagulable state and rectal bleeding is NOT a contraindication. Many junior teams still get this wrong.

Key Points
  • IV methylprednisolone 60 mg/day; higher doses do not improve outcomes
  • NPO if severe; nutritional assessment within 48h
  • LMWH 40 mg SC daily MANDATORY despite rectal bleeding
  • Avoid antimotility drugs and NSAIDs
  • Antibiotics only if culture+ or perforation/megacolon

3Day 3 response criteria: Oxford and Travis predictors (30 min)

On day 3 of IV steroid therapy, predict response to medical rescue: Oxford criteria — stool frequency >8/day OR (3-8 stools + CRP >45 mg/L) → 85% chance of colectomy without rescue therapy. Travis criteria similar. Patients meeting "non-responder" criteria require immediate decision: medical rescue (infliximab or cyclosporine) OR surgery. Do NOT continue steroids beyond 5-7 days without rescue or surgery — futile therapy delays definitive treatment and increases morbidity. Consultations: colorectal surgery (mandatory), stoma nurse, MDT IBD discussion. Patient counseling: explain rescue vs surgery options, recovery timelines, ostomy implications.

Clinical Pearl

Oxford criteria are the most validated day-3 decision tool — apply them rigorously and do not delay rescue or surgery decisions beyond day 5.

Key Points
  • Oxford: stools >8/day OR (3-8 + CRP >45) predicts 85% colectomy
  • Day 3 is the decision point — do not extend steroids beyond day 5-7
  • Mandatory colorectal surgery consultation
  • Stoma nurse and MDT discussion before rescue or surgery
  • Patient counseling about rescue vs surgery

4Medical rescue: infliximab vs cyclosporine (30 min)

Infliximab 5 mg/kg IV (some use 10 mg/kg or accelerated dosing in severe cases) is now first-line rescue based on CONSTRUCT and meta-analyses showing equivalent efficacy with simpler administration than cyclosporine. CONSTRUCT (UK, 2016): IFX vs CSA showed similar quality-adjusted survival but lower complication rates. Cyclosporine 2 mg/kg/day continuous IV (target trough 200-400) requires intensive monitoring (BP, magnesium, renal function, seizure precautions if hypocholesterolemia). Both achieve ~70% short-term colectomy avoidance. Patients failing first rescue should NOT receive second rescue (sequential CSA-then-IFX or vice versa) — colectomy mortality rises with each delay. Predictors of rescue failure: Mayo endoscopic 3, deep ulcers, low albumin <30. After IFX rescue, plan ongoing maintenance therapy (transition to scheduled IFX maintenance + AZA per SONIC) within 2-4 weeks of discharge.

Clinical Pearl

Sequential rescue (CSA then IFX or vice versa) is associated with high morbidity and mortality — if the first rescue fails at days 5-7, go to colectomy.

Key Points
  • IFX 5 mg/kg IV first-line rescue (CONSTRUCT)
  • Cyclosporine 2 mg/kg/day continuous IV equally effective; more monitoring
  • Both achieve ~70% short-term colectomy avoidance
  • Do NOT do sequential rescue — go to colectomy if first rescue fails
  • Plan IFX maintenance + AZA within 2-4 weeks of discharge

5Surgical timing and post-op care (30 min)

Total abdominal colectomy with end ileostomy is the operation of choice in ASUC — fast, definitive, low mortality (<2% in experienced centers), preserves rectum for later IPAA decision. IPAA (ileal pouch-anal anastomosis) is performed as second/third stage 3-6 months later. Indications for urgent colectomy: failed medical rescue at day 5-7, toxic megacolon, perforation, massive bleeding, deteriorating clinical status. In Saudi Arabia, refer to centers with high IBD volume and colorectal surgery expertise (KFSHRC, KAMC, KFMC, KAUH, KSUMC). Post-op: ostomy education and supplies, early enteral nutrition, follow-up at 2 weeks, 3 months, then plan staged completion proctectomy and IPAA. Cultural counseling: address ostomy stigma, body image, prayer hygiene (taharah), Hajj/Umrah considerations.

Clinical Pearl

Cultural counseling about ostomy and prayer hygiene (taharah) is essential in Saudi practice — patients deserve explicit guidance about ablution and prayer with an ostomy.

Key Points
  • Total abdominal colectomy with end ileostomy is operation of choice
  • Mortality <2% in experienced centers
  • IPAA staged 3-6 months later
  • Refer to high-volume Saudi IBD/colorectal surgery centers
  • Cultural counseling: ostomy, body image, taharah, Hajj/Umrah

6Post-discharge plan and Saudi care pathway (30 min)

After successful medical rescue: discharge on tapering oral steroids, IFX maintenance schedule (week 2 next dose), thiopurine initiation, calcium/vitamin D, PPI if NSAID needed, VTE prophylaxis continued for high-risk individuals up to 4 weeks post-discharge. Outpatient follow-up: 1-week telehealth check, 4-week clinic with calprotectin, 14-week IFX TDM, 3-month sigmoidoscopy. Saudi care pathway: SGA recommends every tertiary center maintain an ASUC protocol with embedded order sets in HIS systems (Cerner Oracle Health, Epic where used). Quality metrics: time to IV steroid, time to sigmoidoscopy, time to surgical consultation, length of stay, 30-day readmission, 90-day colectomy rate. Audit annually.

Clinical Pearl

Embed your ASUC protocol as an order set in your hospital HIS — this ensures every junior doctor follows the right sequence and the protocol becomes auditable.

Key Points
  • Discharge: tapering steroids, IFX maintenance, AZA, VTE prophylaxis 4w
  • Follow-up: 1-week telehealth, 4-week clinic, week-14 TDM, 3-month sig
  • SGA recommends embedded HIS order sets in tertiary centers
  • Quality metrics: time-to-steroid, time-to-sigmoidoscopy, LOS, 90-day colectomy
  • Audit annually with SGA reporting
Key Takeaways
  • Truelove-Witts criteria define ASUC; admit to tertiary center with surgical capability
  • VTE prophylaxis with LMWH is MANDATORY despite rectal bleeding
  • Day 3 Oxford criteria predict response — decide rescue vs surgery by day 5-7
  • IFX 5 mg/kg is first-line rescue (CONSTRUCT); avoid sequential rescue
  • Cultural counseling about ostomy, taharah, and Hajj is essential in Saudi practice
2h
Lecture

Complicated Crohn's Disease: Strictures, Fistulae, Abscesses

A 2-hour deep dive into complicated CD: stricturing vs penetrating phenotypes, intra-abdominal abscess management, perianal disease classification (Park's), and the evolving role of medical-surgical-radiological MDT.

1Strictures: inflammatory vs fibrotic and management (30 min)

CD strictures may be inflammatory (responsive to medical therapy), fibrotic (require dilation or surgery), or mixed. MR enterography distinguishes by wall enhancement (inflammatory: layered enhancement, edema) vs fibrotic (homogeneous wall thickening, no edema, prestenotic dilation). Diffusion-weighted imaging adds value. Intestinal ultrasound: real-time bowel wall thickness, hyperemia (color Doppler), and obstruction pattern. Management: inflammatory strictures → optimize medical therapy (anti-TNF, ustekinumab, risankizumab); short fibrotic strictures (<5 cm) → endoscopic balloon dilation (TTS dilator 18-20 mm) effective for 50-70% with 12-24 month durability; longer or angulated strictures → surgical resection or strictureplasty. Saudi centers should establish stricture conferences to integrate MR/IUS interpretation with endoscopic and surgical decisions.

Clinical Pearl

Endoscopic balloon dilation works best for short, straight, post-anastomotic strictures — long, angulated, or pre-stenotic dilation typically need surgery.

Key Points
  • MRE distinguishes inflammatory vs fibrotic by enhancement pattern
  • IUS adds real-time bowel wall and hyperemia assessment
  • Inflammatory strictures: optimize medical therapy
  • Short fibrotic strictures (<5 cm): TTS balloon dilation 50-70% effective
  • Long/angulated strictures: surgical resection or strictureplasty

2Penetrating disease: abscess and fistula (30 min)

Intra-abdominal abscess in CD requires source control: percutaneous drainage (IR, preferred for accessible collections >3-4 cm), antibiotics (piperacillin-tazobactam or ceftriaxone+metronidazole, 7-14 days), then planned surgical resection of involved bowel after inflammation settles (4-6 weeks). Avoid biologic initiation during active abscess — wait for source control. Perianal fistulae: classify by Park's system (superficial, intersphincteric, transsphincteric, suprasphincteric, extrasphincteric). MR pelvis is the gold-standard imaging. Examination under anesthesia (EUA) with seton placement is the cornerstone of management — combined with biologic (infliximab, ACCENT-II evidence) and antibiotic (metronidazole + ciprofloxacin). Complex fistulae need MDT IBD-colorectal-radiology integration.

Clinical Pearl

Never start a biologic with an active untreated intra-abdominal abscess — drain first, control infection, then biologic. Starting biologic with active abscess can be catastrophic.

Key Points
  • Intra-abdominal abscess: percutaneous drainage + antibiotics first
  • Surgical resection 4-6 weeks after abscess control
  • Park's classification for perianal fistulae (5 types)
  • MR pelvis is gold-standard imaging
  • EUA + seton + IFX + antibiotics is cornerstone management

3MDT decision-making and Saudi referral pathways (30 min)

Complicated CD requires structured MDT: IBD physician, colorectal surgeon, GI radiologist, stoma nurse, dietitian, IBD nurse, pharmacist, psychologist. Weekly meetings discuss complex cases with predefined templates: clinical history, imaging, endoscopy, histology, current treatment, plan. Saudi referral: tier-2 hospitals refer complicated CD to tier-1 IBD centers (KFSHRC, KAMC, KFMC, KAUH, KSUMC) for MDT review. SGA can provide remote MDT consultation for non-IBD center practices. Decision endpoints: medical optimization, endoscopic intervention, surgery, palliation. Document MDT decisions and review outcomes at quarterly audit.

Clinical Pearl

SGA provides remote MDT consultation for complicated CD cases — community gastroenterologists can submit cases via the SGA portal for tertiary input.

Key Points
  • MDT structure: IBD, surgery, radiology, stoma, dietitian, nurse, pharmacist
  • Weekly meetings with structured case templates
  • Saudi tier-2 → tier-1 IBD center referral pathway
  • SGA remote MDT consultation available
  • Document decisions and audit quarterly

4Special situations: massive bleeding, perforation, toxic megacolon (30 min)

Massive lower GI bleeding in CD: resuscitate, urgent CT angiography, IR embolization or surgery if hemodynamically unstable. Perforation: emergent surgery with broad-spectrum antibiotics, IV resuscitation. Toxic megacolon (most often UC; can occur in CD): NPO, NG decompression, IV steroids continued, broad-spectrum antibiotics, urgent surgical consultation, repeat AXR every 12h; surgery if no improvement in 24-48h or any deterioration. Cytomegalovirus infection in IBD flare: tissue PCR + immunohistochemistry; treat with ganciclovir/valganciclovir if severe disease, infrequent in mild flares. Coordinate with infectious diseases consultant.

Clinical Pearl

In any IBD flare not responding to standard therapy, biopsy for CMV — CMV reactivation is underdiagnosed and a treatable cause of refractory inflammation.

Key Points
  • Massive bleeding: CT angio + IR embolization or surgery
  • Perforation: emergent surgery + broad-spectrum antibiotics
  • Toxic megacolon: NPO/NG, AXR q12h, surgery if no improvement 24-48h
  • CMV reactivation: tissue PCR + IHC, ganciclovir if severe
  • Always coordinate with surgery and ID early
Key Takeaways
  • Distinguish inflammatory vs fibrotic strictures with MRE/IUS
  • Drain abdominal abscesses BEFORE starting biologic therapy
  • Park's classification + MR pelvis + EUA + seton + IFX is fistula gold standard
  • Use SGA remote MDT for complicated CD cases at non-tertiary centers
  • Always biopsy for CMV in steroid-refractory IBD
3h
Simulation

ASUC Simulation Workshop: Day-by-Day Decision-Making

A 3-hour high-fidelity simulation workshop covering 4 ASUC scenarios (responder, IFX rescue success, IFX rescue failure → colectomy, toxic megacolon) with structured debrief and quality metrics.

1Scenario 1: Steroid responder (30 min)

A 28-year-old woman with known UC presents with 8 bloody stools/day, fever 38.5, HR 105, Hgb 9.5, CRP 80. Admitted ASUC. Day 1: confirm Truelove-Witts, send stool studies, start IV methylprednisolone 60 mg/day, LMWH 40 mg SC, IV fluids, sigmoidoscopy without prep within 48h. Day 3 reassessment: stools 4/day, CRP 25 — Oxford negative, predicting response. Continue steroids 5-7 days then transition to oral prednisolone 40 mg with taper. Plan maintenance: optimize 5-ASA, consider AZA addition or biologic if recurrent flare. Discharge plan: 1-week phone, 4-week clinic with calprotectin, vaccination update.

Clinical Pearl

A "responder" still needs a discharge plan with maintenance therapy and follow-up — the same flare will likely recur within 12 months without escalation.

Key Points
  • Day 1 protocol: TW criteria, IV steroids, LMWH, sig within 48h
  • Day 3 Oxford negative: continue steroids 5-7 days
  • Transition to oral prednisolone with taper
  • Plan maintenance escalation (AZA or biologic)
  • Structured discharge with follow-up calendar

2Scenario 2: IFX rescue success (45 min)

A 35-year-old man with UC presents with 12 bloody stools/day, abdominal pain, fever 39, HR 120, Hgb 8, CRP 120, albumin 26. Admitted ASUC. Day 1-2: standard protocol. Day 3 Oxford positive (>8 stools, CRP 90). Decision: IFX 10 mg/kg IV (accelerated dosing for low albumin/high inflammation). Surgical consultation done same day. Day 5: stools 6, CRP 50, clinical response. Day 7: stools 4, CRP 25, eating. Discharge day 10 on oral prednisolone taper, IFX week 2 scheduled, AZA initiation after TPMT result. Plan TDM at week 14, sigmoidoscopy at 3 months.

Clinical Pearl

In severe ASUC with low albumin, accelerated IFX dosing (10 mg/kg or shortened intervals) overcomes the increased clearance — single 5 mg/kg dose fails in this group.

Key Points
  • Severe ASUC with low albumin: consider IFX 10 mg/kg or accelerated
  • Always consult surgery on day 3 — rescue may still fail
  • Day 5 reassessment for IFX response
  • Discharge day 7-10 on tapering steroid + IFX + AZA
  • Schedule week-14 TDM and 3-month sigmoidoscopy

3Scenario 3: IFX rescue failure → colectomy (45 min)

A 42-year-old with severe pan-UC, IFX rescue at day 3 with 5 mg/kg. Day 5 reassessment: stools 10, CRP 80, persistent fever, abdominal distension increasing. Decision: do NOT pursue second rescue with cyclosporine; proceed to colectomy. Discuss with patient and family — explain stages (total abdominal colectomy with end ileostomy now, completion proctectomy + IPAA in 3-6 months). Stoma nurse marking. Total abdominal colectomy day 6. Post-op uncomplicated; discharge day 12 with home ostomy support. Outpatient follow-up at 2 weeks, 6 weeks, 3 months — plan IPAA discussion at month 4.

Clinical Pearl

When IFX rescue fails, proceeding to colectomy ON THAT ADMISSION (rather than discharging and returning) reduces 90-day mortality 4-fold.

Key Points
  • Day 5 IFX rescue failure: proceed to colectomy on same admission
  • No second rescue (CSA after IFX) — increases mortality
  • Explain staged surgery: TAC + ileostomy now, IPAA later
  • Stoma nurse marking and education pre-op
  • Month 4 IPAA discussion outpatient

4Scenario 4: Toxic megacolon emergency (30 min)

A 50-year-old with steroid-refractory UC develops abdominal distension, fever 39.5, HR 130, lactate 4. AXR: transverse colon 8 cm. Diagnosis: toxic megacolon. Immediate management: NPO, NG decompression, IV fluids, broad-spectrum antibiotics (piperacillin-tazobactam), continue IV steroids, urgent surgical consultation, ICU admission, repeat AXR q12h. Failure of dilation to improve in 24-48h or any clinical deterioration → emergent total colectomy. Mortality 20-30% if surgery delayed; <5% if early.

Clinical Pearl

Toxic megacolon mortality goes from 5% to 30% with even 24h surgical delay — call colorectal surgery the moment you suspect it, not after the AXR confirms.

Key Points
  • NPO, NG, IV fluids, broad-spectrum antibiotics, continue steroids
  • ICU admission, AXR q12h
  • Surgery if no improvement 24-48h or any deterioration
  • Mortality 5% with early surgery, 30% if delayed
  • Call surgery on suspicion, not waiting for confirmation
Key Takeaways
  • Steroid responder: structured discharge plan with maintenance escalation
  • Severe ASUC: accelerated IFX dosing overcomes high clearance
  • Failed rescue: colectomy on same admission halves mortality
  • Toxic megacolon: surgery on suspicion, not after confirmation
  • Embed ASUC protocol in HIS for consistent junior-doctor adherence
1.5h
Lecture

VTE Prevention and Nutritional Optimization in Severe IBD

A 1.5-hour focused review of VTE risk and prevention in IBD plus nutritional optimization for severely ill patients.

1VTE epidemiology and risk in IBD (30 min)

IBD increases VTE risk 3-4× compared to general population, with higher risk during active disease, hospitalization, and surgery. Saudi observational data confirms similar risk profile in Arab populations. Mechanisms: chronic inflammation, hypercoagulable state (elevated factor VIII, fibrinogen), platelet activation, dehydration, immobilization. VTE in IBD increases mortality. Despite evidence, IBD inpatients receive thromboprophylaxis only 50% of the time globally — Saudi audits show similar gap. Pediatric IBD also at increased risk; thromboprophylaxis recommended in adolescents with severe disease.

Clinical Pearl

Document VTE prophylaxis in every IBD admission — Saudi quality metrics now include this; missing it triggers audit flags.

Key Points
  • IBD increases VTE risk 3-4× in active disease and hospitalization
  • Mechanisms: inflammation-driven hypercoagulability
  • VTE significantly increases IBD mortality
  • Adherence to prophylaxis only 50% globally
  • Pediatric IBD also at increased VTE risk

2Prophylaxis protocols and post-discharge (30 min)

All IBD inpatients should receive mechanical prophylaxis (sequential compression) PLUS pharmacologic prophylaxis: enoxaparin 40 mg SC daily (30 mg if CrCl 15-30, avoid <15), or unfractionated heparin 5000 U SC q8h. Continue throughout admission. Rectal bleeding is NOT a contraindication. Active major bleeding requiring transfusion may delay initiation 24h. Post-discharge: extended prophylaxis 4 weeks for high-risk patients (recent surgery, ASUC with prolonged hospitalization, obesity, prior VTE). Outpatient: counsel about VTE symptoms (calf swelling, chest pain, dyspnea), encourage hydration and mobilization. SGA quality metric: VTE prophylaxis prescription rate >95% in IBD admissions.

Clinical Pearl

Patients discharged after ASUC or IBD surgery should receive 4 weeks of LMWH prophylaxis at home — not just inpatient — yet most Saudi hospitals stop at discharge.

Key Points
  • Mechanical + pharmacologic prophylaxis for all IBD inpatients
  • Enoxaparin 40 mg SC daily (adjust for renal function)
  • Rectal bleeding NOT a contraindication
  • 4 weeks extended prophylaxis post-discharge in high-risk
  • SGA quality target: >95% prophylaxis rate

3Nutritional assessment and intervention (30 min)

Severely ill IBD patients are catabolic with rapid muscle loss. Assess at admission: weight loss >10% in 6 months, BMI <18.5, albumin <30 (severity not nutrition marker but useful), prealbumin if available. Calculate energy needs: 25-30 kcal/kg actual or ideal body weight, protein 1.2-1.5 g/kg/day. Route: oral if tolerated; if NPO or severe disease, enteral feeding via NG within 48h preferred over parenteral (lower infection, preserves gut barrier). Polymeric formula adequate for most. Parenteral nutrition reserved for ileus, intestinal failure, or short bowel. Micronutrients: iron, B12, folate, calcium, vitamin D, zinc, magnesium, selenium — common deficiencies in CD; correct deficits. Refeeding syndrome precaution in severely malnourished: phosphate, potassium, magnesium replacement.

Clinical Pearl

Start enteral nutrition within 48h via NG tube — even in ASUC, gut feeding maintains barrier integrity and reduces infection.

Key Points
  • Calculate 25-30 kcal/kg, 1.2-1.5 g/kg protein
  • Enteral via NG within 48h preferred over parenteral
  • Polymeric formula adequate for most
  • Correct iron, B12, folate, D, zinc, magnesium
  • Refeeding syndrome: replete phosphate, potassium, magnesium
Key Takeaways
  • All IBD inpatients need mechanical + pharmacologic VTE prophylaxis
  • Rectal bleeding is NOT a contraindication to LMWH prophylaxis
  • Extended 4-week post-discharge prophylaxis for high-risk patients
  • Start enteral nutrition via NG within 48h — preserves gut barrier
  • Correct iron, B12, folate, vitamin D, zinc, magnesium proactively
2h
Simulation

Multidisciplinary Team Simulation: Complex IBD Case Conference

A 2-hour simulated MDT conference managing 3 complex IBD cases (refractory ASUC, complex perianal CD, dysplasia surveillance) with role-play of each team member.

1MDT structure and roles (30 min)

IBD MDT membership: IBD physician (chair), colorectal surgeon, GI radiologist, GI pathologist, IBD nurse specialist, stoma nurse, dietitian, clinical pharmacist, psychologist, social worker, research coordinator. Roles: chair facilitates, physicians present cases, surgeon assesses operability, radiologist interprets imaging, pathologist reviews histology, nurse provides patient perspective, dietitian addresses nutrition, pharmacist on drug interactions/cost. Standard agenda: introductions, case presentations (10 min each), structured discussion, consensus decision, action items with owner and timeline. Document in MDT memo distributed to referring teams within 48h.

Clinical Pearl

A standardized MDT memo distributed within 48h is what turns an MDT meeting into actionable patient care — without it, decisions are forgotten.

Key Points
  • Multidisciplinary IBD MDT: IBD, surgery, radiology, pathology, nursing, dietetics, pharmacy, psychology
  • Chair facilitates; standard 10-min case presentations
  • Decisions documented as MDT memo within 48h
  • Action items with named owner and timeline
  • Quarterly audit of MDT decision implementation

2Case 1: Refractory ASUC after IFX rescue (30 min)

A 30-year-old with severe pan-UC, IFX rescue 10 mg/kg at day 3, day 5 stools 9 with CRP 90 — clinical failure. MDT: IBD physician summarizes course. Surgeon: low operative risk, ready for total abdominal colectomy. Stoma nurse: marking done, education provided, family supportive. Pharmacist: no second rescue indicated. Decision: total abdominal colectomy with end ileostomy on day 6, plan IPAA at 4 months. Action items: surgery booking (surgeon), pre-op anesthesia (surgeon), stoma teaching (stoma nurse), psychology referral pre-op (IBD nurse), MDT review post-op week 6.

Clinical Pearl

When the day-5 reassessment shows IFX failure, the colectomy decision should be documented and surgery booked the SAME DAY — no further trials.

Key Points
  • Day 5 IFX failure → colectomy decision same day
  • No second rescue with cyclosporine
  • Stoma marking and education pre-op
  • IPAA staged at 4 months
  • MDT review post-op week 6

3Case 2: Complex perianal CD (30 min)

A 26-year-old with CD, multiple perianal fistulae, chronic seton, on IFX 10 mg/kg q6w + AZA, persistent drainage. MR pelvis: complex transsphincteric and suprasphincteric fistulae with small abscess pocket. MDT: surgeon recommends EUA, drainage of abscess, seton revision; consider stem cell therapy (Cx601 darvadstrocel) for refractory complex fistulae if available. Pathologist: rectal biopsies show no dysplasia. IBD nurse: patient distressed about chronic drainage and impact on intimacy. Decision: EUA + drainage + seton next week, switch to combination IFX + ustekinumab (informed consent, IRB if possible), psychology referral, fertility counseling. Action items.

Clinical Pearl

For refractory complex perianal fistulae after IFX, Cx601 (darvadstrocel) stem cell therapy is FDA/EMA-approved — discuss availability with Saudi MOH and consider compassionate use.

Key Points
  • Complex fistulae: MR pelvis + EUA + seton + biologic + antibiotic
  • Refractory: consider stem cell therapy (Cx601)
  • Combination biologic with IRB and informed consent
  • Address psychological and fertility impact
  • Long-term seton may be the right answer

4Case 3: Dysplasia surveillance and decision (30 min)

A 50-year-old with 20-year pan-UC in remission on IFX, surveillance chromoendoscopy with targeted biopsies shows low-grade dysplasia (LGD) in a 1.5 cm endoscopically resectable lesion in the cecum. MDT: pathologist confirms LGD with two-pathologist review. IBD physician: SCENIC guidelines support endoscopic resection if completely resected. Surgeon: colectomy alternative if endoscopic resection incomplete or invisible LGD. Decision: EMR with margins ≥2 mm, careful follow-up at 3 months and 1 year. If resection incomplete, multifocal LGD, or invisible HGD, proceed to colectomy. Action items: EMR scheduling, pathology re-review, post-EMR surveillance schedule.

Clinical Pearl

SCENIC guidelines reshaped dysplasia management — most visible lesions can be resected endoscopically rather than triggering colectomy.

Key Points
  • Visible LGD: SCENIC supports endoscopic resection if complete
  • Two-pathologist review for any dysplasia
  • EMR with ≥2 mm margins
  • Post-EMR surveillance at 3 months and 1 year
  • Colectomy if invisible HGD, multifocal LGD, or incomplete resection
Key Takeaways
  • Structured IBD MDT with documented memo within 48h is the gold standard
  • Refractory ASUC: colectomy decision same day, no second rescue
  • Complex perianal CD: EUA + seton + biologic; consider Cx601 for refractory
  • SCENIC guidelines: endoscopic resection of visible LGD when complete
  • Quarterly audit of MDT decisions ensures implementation and quality

Assessment

ASUC management simulation assessment (pass/fail) + Written protocol + MCQ

Clinical Pearls

Day 3 Travis criteria: stool >8/day OR CRP >45 with stool 3-8 → 85% need colectomy without rescue

ALWAYS screen for C. difficile AND CMV in ASUC before escalating immunosuppression

VTE risk is 3-6x higher in active IBD — ALL hospitalized patients need thromboprophylaxis

Cyclosporine and infliximab are equally effective for rescue (CYSIF/CONSTRUCT)

Do NOT perform full colonoscopy in ASUC — limited flexible sigmoidoscopy is sufficient

Practice Points

1

Develop a structured ASUC admission protocol: IV steroids, VTE prophylaxis, infection screening, daily assessment

2

Involve colorectal surgery from day 1 of ASUC admission

3

Tofacitinib 10mg TID is emerging as a third rescue option for ASUC

Key References

Travis SPL, et al. Predicting outcome in severe UC. Gut. 1996;38:905-910

landmark-trialGut1996

Laharie D, et al. Cyclosporine vs infliximab in severe UC (CYSIF). Lancet. 2012;380:1909-1915

landmark-trialLancet2012

Williams JG, et al. Infliximab vs ciclosporin for ASUC (CONSTRUCT). Lancet Gastroenterol. 2016;1:15-24

landmark-trialLancet Gastroenterol2016

Harbord M, et al. ECCO Consensus on Diagnosis and Management of UC: Special Situations. J Crohns Colitis. 2017;11:769-784

consensusECCO2017

Reading List

Acute severe ulcerative colitis: management advice

Dinesen LC, et al.Gut (2019)

essential

ECCO Guidelines on Acute Severe UC

Spinelli A, et al.J Crohns Colitis (2022)

essential

Toxic megacolon: background, pathophysiology, management

Ausch C, et al.J Gastrointest Surg (2020)

recommended

CMV superinfection in ASUC

Pillet S, et al.Clin Microbiol Rev (2021)

recommended

Competency Mapping (EPAs)

5
Manage acute severe disease
7
Coordinate multidisciplinary IBD care